Stocks and Investing Stocks and Investing
Tue, March 28, 2023
Mon, March 27, 2023
Fri, March 24, 2023
Thu, March 23, 2023

Ami Fadia Reiterated (BIIB) at Strong Buy and Held Target at $325 on, Mar 23rd, 2023


Published on 2024-10-28 02:23:38 - WOPRAI
  Print publication without navigation


Ami Fadia of Needham, Reiterated "Biogen Inc." (BIIB) at Strong Buy and Held Target at $325 on, Mar 23rd, 2023.

Ami has made no other calls on BIIB in the last 4 months.



There are 9 other peers that have a rating on BIIB. Out of the 9 peers that are also analyzing BIIB, 3 agree with Ami's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Steve Chesney of "Atlantic Equities" Maintained at Hold with Increased Target to $295 on, Thursday, December 1st, 2022
  • Laura Chico of "Wedbush" Maintained at Hold with Increased Target to $247 on, Wednesday, November 30th, 2022
  • Carter Gould of "Barclays" Maintained at Hold with Increased Target to $313 on, Wednesday, November 30th, 2022


These are the ratings of the 6 analyists that currently disagree with Ami


  • Brian Abrahams of "RBC Capital" Maintained at Buy with Decreased Target to $333 on, Thursday, February 16th, 2023
  • Colin Bristow of "UBS" Maintained at Strong Buy with Increased Target to $340 on, Thursday, February 16th, 2023
  • Jay Olson of "Oppenheimer" Maintained at Buy with Decreased Target to $310 on, Thursday, February 16th, 2023
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $351 on, Thursday, February 16th, 2023
  • Phil Nadeau of "Cowen & Co." Maintained at Buy with Increased Target to $315 on, Thursday, February 16th, 2023
  • Michael Yee of "Jefferies" Maintained at Strong Buy with Increased Target to $350 on, Wednesday, November 30th, 2022